Physician profile
Darius Zagunis
NPI 1174542286
$6,313.71
in general payments reported to CMS, 2019-2025
29 companies · $2,467 in 2025
The $2,467 reported for 2025 was more than what 82% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $493 · 2021: $985 · 2022: $729 · 2023: $441 · 2024: $478 · 2025: $2,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,973 · Travel and Lodging: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,972.94 |
| Travel and Lodging | $1,412.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,335.89 | 2019-2025 | Proclaim, Eterna |
| Spinefrontier, INC. | $1,574.08 | 2021-2025 | Facetfuse, Inspan, Nanofuse |
| Nevro Corp. | $529.08 | 2019-2024 | Senza |
| Teva Pharmaceuticals USA, INC. | $288.81 | 2019-2021 | |
| Medtronic, INC. | $270.23 | 2021-2025 | Intellis Adaptivestim |
| Boston Scientific Corporation | $169.19 | 2019-2022 | |
| Mml US, INC. | $116.17 | 2025 | Reactiv8 |
| Si-Bone, INC. | $103.94 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $100.11 | 2019-2021 | |
| Allergan, INC. | $96.95 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $70.95 | 2025 | |
| Biotronik Nro, INC. | $69.11 | 2023 | Biotronik |
| Averitas Pharma INC. | $65.67 | 2023-2025 | Qutenza |
| Alevio, LLC | $65.02 | 2023 | Sicure Sacroiliac Joint Fusion System |
| Arbor Pharmaceuticals, INC. | $52.77 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $51.93 | 2020-2023 | Ztlido |
| Pfizer INC. | $49.94 | 2019 | |
| Lundbeck LLC | $46.67 | 2021 | |
| Medtronic USA, INC. | $34.88 | 2019-2020 | |
| Abbvie INC. | $33.43 | 2022 | |
| Globus Medical, INC. | $31.63 | 2025 | Senza |
| Collegium Pharmaceutical, INC. | $28.98 | 2021-2023 | Nucynta |
| Biohaven Pharmaceuticals, INC. | $24.74 | 2021 | |
| Fidia Pharma USA INC. | $21.72 | 2025 | Hymovis, Triluron |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.76 | 2023 | Relistor |
| Mdd US Operations, LLC | $17.48 | 2019 | |
| Ferring Pharmaceuticals INC. | $17.37 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.83 | 2024 | Horizant |
| Zyla Life Sciences, INC. | $14.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darius Zagunis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.